Treatment of Neuroendocrine Tumors with LU 177 Dotatate
Recorded On: 11/02/2019
The speaker will detail the main indication for Lutetium-177 dotatate treatment, how to screen and select the appropriate patient for referral, and the main benefits and risks of the treatment. This lecture was recorded on November 02, 2019 at the 2019 ACOI Annual Convention and Scientific Sessions held in Phoenix, AZ.
Mark Tulchinsky, MD
Professor of Radiology and Medicine
CCD President-Elect (2020), the American College of Nuclear Medicine, Professor of Radiology and Medicine Associate Director, Nuclear Medicine Penn State Health, MiltonS. Hershey Medical Center Hershey, PA